FDA facts provide the public with clear, science-based information about how the agency protects food, drugs, devices, and other products. Understanding these facts helps consumers, professionals, and policymakers make safer, more informed decisions.
This resource outlines core FDA structures, product oversight areas, and expectations for transparency and compliance. The following sections detail key topics with a quick-reference table, regulatory scopes, and real-world guidance.
| Product Area | Regulating Office | Key Legal Authority | Typical Review Path |
|---|---|---|---|
| Human Drugs | CDER | FD&C Act, Federal Food, Drug, and Cosmetic Act | IND, Phase 1–3 trials, NDA, post-market surveillance |
| Medical Devices | CDRH | FD&C Act, Medical Device Amendments | 510(k), De Novo, PMA, UDI implementation |
| Food & Dietary Supplements | FSB | FD&C Act, DSHEA | Pre-submission meetings, GRAS notifications |
| Biologics & Vaccines | CBER | PHS Act, FD&C Act | IND, BLA licensure, lot release |
| Tobacco Products | CTP | FDA Tobacco Act | PMTA, pre-market review, advertising oversight |
Human Drug Regulation and Approval Pathways
The Center for Drug Evaluation and Research oversees human drugs through a structured development lifecycle. Sponsors submit Investigational New Drug applications before Phase 1 trials and New Drug Applications after Phase 3 evidence is complete.
Priority review, accelerated approval, and breakthrough therapy designations can expedite access for serious conditions. Post-approval requirements such as Phase 4 studies and risk evaluation and mitigation strategies ensure ongoing safety monitoring.
Medical Device Oversight and Risk Classification
CDRH classifies devices into three panels based on risk, which determines the regulatory route. Most low-risk devices follow the 510(k) pathway, demonstrating substantial equivalence to a predicate.
Higher-risk devices may require Pre-Submission meetings, De Novo requests, or PMA, which demand rigorous clinical data. Unique Device Identification and post-market reporting help track performance across the product lifecycle.
Food Safety, Labeling, and Dietary Supplement Rules
FSB enforces Good Manufacturing Practices and hazard analysis requirements for food facilities, while dietary supplements follow DSHEA standards. Facility registration, mandatory recall authority, and labeling compliance protect consumers from contamination and false claims.
Structure/function claims for supplements must include a disclaimer, and new dietary ingredients require notification. Import and export programs strengthen supply chain integrity and prevent adulterated products from entering the market.
Biologics, Vaccines, and Blood Product Oversight
CBER regulates vaccines, blood derivatives, and cellular and gene therapy products under a hybrid framework that combines drug and biological product standards. License applications include CMC documentation, nonclinical studies, and clinical trials that demonstrate safety and efficacy.
Lot release review, pharmacovigilance systems, and adverse event reporting ensure continuous protection. Guidance documents and emerging science on gene editing further refine oversight to keep pace with innovation.
Key Takeaways on FDA Facts and Practices
- Understand product-specific regulatory pathways to ensure compliant development and submission strategies.
- Leverage FDA designations such as breakthrough therapy or priority review where appropriate to accelerate timelines.
- Implement robust quality systems, documentation, and post-market surveillance to maintain approval and market access.
- Stay current with guidance documents, advisory committee recommendations, and policy updates to align with evolving standards.
FAQ
Reader questions
What does the FDA review before approving a new drug application?
The FDA reviews chemistry, manufacturing, and controls data, nonclinical and clinical study results, labeling proposals, and patient information materials to assess safety, effectiveness, and quality.
How does the FDA classify medical devices and determine the regulatory pathway?
Devices are classified into Panels I, II, or III based on risk, which directs whether they use 510(k), De Novo, or PMA pathways, with additional requirements such as UDI and post-market reporting.
What records must food facilities maintain to comply with FDA regulations?
Facilities must keep written safety plans, hazard analysis records, temperature and sanitation logs, recall procedures, and traceability documentation to meet Current Good Manufacturing Practice and FSMA requirements.
What post-approval obligations does the FDA require for biologics and vaccines?
Sponsors must conduct Phase 4 studies, submit lot information for release, monitor adverse events, update risk management plans, and comply with labeling changes based on new evidence.